Dear colleagues,
Respiratory Syncytial Virus (RSV) is a common cause of childhood acute lower respiratory infection that leads to hospitalizations and deaths, particularly in children younger than 6 months. Product development efforts are underway to make available a monoclonal antibody (mAb) that protects infants from RSV. PATH is currently collecting feedback on the most appropriate container/device to administer one such RSV mAb to infants. The goal of the project is to inform infant RSV mAb product development.
We would like to invite TechNet members with expertise in childhood immunizations to complete an online survey to contribute feedback in selecting the most appropriate container/device to administer the RSV mAb product to infants. The survey should take 10-20 minutes to complete and can be accessed until November 30, 2021 by clicking on the link here: RSV mAb stakeholder survey.
If the link above does not work, try copying the link below into your web browser:
https://redcap.iths.org/surveys/?s=K7DJMCRWK4LLLFRL
Your contributions are invaluable to this effort, and we look forward to learning from your insights! Thank you very much, in advance, for your time.
Best,
Collrane Frivold
Technical Officer, Packaging and Delivery Technologies
Medical Devices and Health Technologies Program
PATH
